• Excess Apolipoprotein-B and Cardiovascular Risk, Treating Pulmonary Arterial Hypertension, SGLT2i and CV Outcomes

  • Jun 12 2024
  • Duración: 9 m
  • Podcast

Excess Apolipoprotein-B and Cardiovascular Risk, Treating Pulmonary Arterial Hypertension, SGLT2i and CV Outcomes  Por  arte de portada

Excess Apolipoprotein-B and Cardiovascular Risk, Treating Pulmonary Arterial Hypertension, SGLT2i and CV Outcomes

  • Resumen

  • In this week’s View, Dr. Eagle looks at excess apolipoprotein-B and cardiovascular risk, then examines a recent meta-analysis on treating pulmonary arterial hypertension. Finally, Dr. Eagle shares some thoughts on a SMART-C collaborative meta-analysis of sodium-glucose cotransporter-2 inhibitors and major adverse cardiovascular outcomes.

    Subscribe to Eagle’s Eye View

    Más Menos
activate_primeday_promo_in_buybox_DT

Lo que los oyentes dicen sobre Excess Apolipoprotein-B and Cardiovascular Risk, Treating Pulmonary Arterial Hypertension, SGLT2i and CV Outcomes

Calificaciones medias de los clientes

Reseñas - Selecciona las pestañas a continuación para cambiar el origen de las reseñas.